US009511047B2

(12) **United States Patent**
Roewer et al.

(10) **Patent No.: US 9,511,047 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **DELPHINIDIN FOR COMBATING MELANOMA CELLS**

(71) Applicant: **Sapiotec GmbH**, Wurzburg (DE)

(72) Inventors: **Norbert Roewer**, Wurzburg (DE); **Jens Broscheit**, Wurzburg (DE)

(73) Assignee: **SAPIOTEC GMBH**, Wurzburg (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/651,264**

(22) PCT Filed: **Nov. 28, 2013**

(86) PCT No.: **PCT/EP2013/074991**
§ 371 (c)(1),
(2) Date: **Jun. 11, 2015**

(87) PCT Pub. No.: **WO2014/090586**
PCT Pub. Date: **Jun. 19, 2014**

(65) **Prior Publication Data**

US 2015/0320719 A1 Nov. 12, 2015

(30) **Foreign Application Priority Data**

Dec. 11, 2012 (DE) 10 2012 222 777
Jan. 11, 2013 (EP) 13150909

(51) **Int. Cl.**

A61K 31/54	(2006.01)
A61K 38/21	(2006.01)
A61K 31/352	(2006.01)
A61K 38/19	(2006.01)
A61K 45/06	(2006.01)
A61K 38/17	(2006.01)
A61K 31/7042	(2006.01)
A61K 47/48	(2006.01)
B82Y 5/00	(2011.01)

(52) **U.S. Cl.**
CPC ***A61K 31/352*** (2013.01); ***A61K 31/7042*** (2013.01); ***A61K 38/1793*** (2013.01); ***A61K 38/191*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 47/48969*** (2013.01); *B82Y 5/00* (2013.01)

(58) **Field of Classification Search**
USPC 514/224.2; 424/85.6
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2004/0101933 A1* 5/2004 Matsumoto C07H 17/00 435/75
2005/0013880 A1* 1/2005 Magnuson A61K 31/353 424/732
2007/0232688 A1* 10/2007 Orchansky C07D 307/32 514/461
2009/0270348 A1* 10/2009 Antle A61K 31/724 514/58

FOREIGN PATENT DOCUMENTS

WO WO 2006/076387 7/2006
WO WO 2014/090586 6/2014

OTHER PUBLICATIONS

Biolnik (http://www.biolnik.no/biolnik/cancer-article95-6.html, (2009)).*
Wang et. al. (Cancer let. (2008) 269:281-290).*
Voersmann et. al. (J. Invest. Dermatol. (2012) S129, Abstract #737).*
Lecis et. al. (British Journal of Cancer (2010) 102:1707-1716).*
Hornle et. al. (Oncogene (2011) 30:575-587).*
Ueda et. al. (Drug Develop. Industrial Pharm (1998) 24:863-867).*
Afaq et al., Delphinidin, an Anthocyanidin in Pigmented Fruits and Vegetables, Protects Human HaCaT Keratinocytes and Mouse Skin Against UVB-Mediated Oxidative Stress and Apoptosis, J Invest Dermatology, 2007, 127:222-232.
ATCC product sheet for A-375 [A375] (ATCC CRL-1619), retrieved Nov. 16, 2015, 3 pages.
Biolink, Biolink synthetic anthocyanin molecules becomes cancer fighters,dated May 22, 2009, http://www.biolink.no/biolink/cancer-article95-6.html, retrieved Feb. 21, 2013, 4 pages.
Bruggen, Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies, Cancer Immunol Immunother, 1983, 15:200-205.
Riccardi et al., Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc., 2006, 1:1458-1461.
Serafino et al., Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside, FASEB J, 2004, 18:1940, 25 pages.
Ueda et al., Evaluation of a Sulfobutyl Ether Beta-Cyclodextrin as a Solubilizing/Stabilizing Agent for Several Drugs, Drug Devel Industrial Pharm, 1998, 24:863-867.
Voersmann et al., Three dimensional melanoma treatment using the death ligand TRAIL, 42 Annual Metting of the Eur Society for Dermatological Research, Venice, Italy, Sep. 2012, J Invest Dermatol, Nr. Suppl. 2: S129, Abstract #737, 1 page.
Wang et al., Anthocyanins and their role in cancer prevention, Cancer Lett, 2008, 269:281-290.

* cited by examiner

Primary Examiner — Marcos Sznaidman
(74) *Attorney, Agent, or Firm* — Casimir Jones, S.C.; Mary Ann Brow

(57) **ABSTRACT**

The invention relates to a composition comprising: a complex of delphinidin and a sulfoalkyl ether-β-cyclodextrin and/or delphinidin and the salts thereof as a first component; and a tumour-necrosis factor related apoptosis-inducing ligand (TRAIL) as a second component, for use in the treatment of malignant melanoma.

20 Claims, 21 Drawing Sheets